AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20171425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR and IR formulations
Number of subjects: 53
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-malignant biopsy features (including HGPIN, active inflammation, chronic inflammation, biopsy core length, glandular core length)
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of HGPIN
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Active inflammation
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean core length
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean glandular core length
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean total biopsy length
Number of subjects: 121
Study 17922858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean total glandular length
Number of subjects: 121
Study 17035395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone counseling encouraging a plant-based diet
Number of subjects: 2922
Study 17035395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern change without significant vegetable juice consumption
Number of subjects: 2922
Study 17035395 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 2922
Study 14572817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous purified, pasteurized C1 esterase inhibitor concentrate (Berinert® P) at doses of 500‐1000 IU
Number of subjects: 0
Study 14572817 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 14572817 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-marketing experience since 1985
Number of subjects: 0
Study 11060814 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanthamine (GAL)
Number of subjects: 0
Study 8753712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gram intravenously administered preoperatively and again 15 minutes before skin incision.
Number of subjects: 18
Study 8753712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin clearance preoperatively and intraoperatively.
Number of subjects: 18
Study 8753712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood loss measurement.
Number of subjects: 18
Study 1484852 — intervention group
Group type: EXPERIMENTAL
Intervention: PRES method of bidirectional carotid stimulation (excitation vs. inhibition)
Number of subjects: 32
Study 4049918 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight-oriented psychotherapy
Number of subjects: 51
Study 4049918 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 51
Study 29268024 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral ligament (ALL) reconstruction
Number of subjects: 10
Study 29268024 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Lemaire lateral extra-articular tenodesis (LET)
Number of subjects: 10
Study 29268024 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction alone
Number of subjects: 10
Study 29268024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL reconstruction with either ALL reconstruction or LET
Number of subjects: 10
Study 27179265 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Natural Cycle Frozen-Thawed Embryo Transfer (mNC-FET)
Number of subjects: 959
Study 27179265 — intervention group
Group type: COMPARATOR
Intervention: Artificial Cycle Frozen-Thawed Embryo Transfer (AC-FET)
Number of subjects: 959
Study 25764097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ototopical and systemic antibiotics
Number of subjects: 230
Study 25764097 — intervention group
Group type: COMPARATOR
Intervention: Initial observation
Number of subjects: 230
Study 23864511 — intervention group
Group type: EXPERIMENTAL
Intervention: Food store-based environmental intervention
Number of subjects: 276
Study 20679589 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care intervention for depression; involved a stepped-care model with a nurse depression care manager, clinical pharmacist, and psychiatrist, using electronic medical records and telephone communication.
Number of subjects: 395
Study 18029973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year disease-free survival (DFS)
Number of subjects: 126
Study 18029973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year overall survival (OS)
Number of subjects: 126
Study 15712767 — intervention group
Group type: EXPERIMENTAL
Intervention: Poi consumption (130 g/meal, three times a day for 4 weeks)
Number of subjects: 18
Study 15712767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no poi consumption for 4 weeks)
Number of subjects: 18
Study 15712767 — intervention group
Group type: EXPERIMENTAL
Intervention: Poi consumption
Number of subjects: 18
Study 15712767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 12908031 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian DTPw/Hib combination
Number of subjects: 108
Study 12908031 — intervention group
Group type: COMPARATOR
Intervention: European DTPw/Hib combination
Number of subjects: 108
Study 10566162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacurette
Number of subjects: 200
Study 10566162 — intervention group
Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 200
Study 8684794 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 40
Study 8684794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1845222 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 0
Study 1845222 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 6645208 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate therapy (60 mEq/day)
Number of subjects: 5
Study 6645208 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate therapy
Number of subjects: 5
Study 31411495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ascent cortisol levels
Number of subjects: 22
Study 31411495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid retention during altitude stay
Number of subjects: 22
Study 28299746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Extension (FitEx)
Number of subjects: 36
Study 28299746 — intervention group
Group type: COMPARATOR
Intervention: Active Living Every Day (ALED)
Number of subjects: 36
Study 27132200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mifepristone (200mg oral, 36h before surgery) and misoprostol (400μg oral, 3h before surgery)
Number of subjects: 198
Study 27132200 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (400μg oral, 3h before surgery)
Number of subjects: 198
Study 27132200 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (200mg oral, 36h before surgery)
Number of subjects: 198
Study 27132200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mifepristone and misoprostol
Number of subjects: 198
Study 27132200 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 198
Study 27132200 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone
Number of subjects: 198
Study 25168098 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients with previous CABG
Number of subjects: 1709
Study 25168098 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for graft lesions in CABG patients
Number of subjects: 1709
Study 25168098 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) of native coronary lesions only
Number of subjects: 1709
Study 22350110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU)
Number of subjects: 60
Study 22350110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19293693 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure via the Boussignac system immediately after extubation
Number of subjects: 40
Study 19293693 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen (standard care group)
Number of subjects: 40
Study 17719361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional optimism
Number of subjects: 735
Study 17719361 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk status (high risk)
Number of subjects: 735
Study 15535488 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 5 mg
Number of subjects: 100
Study 15535488 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 100
Study 15535488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15535488 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 2.5 mg
Number of subjects: 100
Study 11832254 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised educational behavioural treatment delivered by cardiac nurses in hospital
Number of subjects: 114
Study 11832254 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study 11408126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel IOL
Number of subjects: 37
Study 11408126 — intervention group
Group type: COMPARATOR
Intervention: Silicone IOL
Number of subjects: 37
Study 9520115 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 4444
Study 9520115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 8293756 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic testing (EPS)
Number of subjects: 486
Study 8293756 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring (HM)
Number of subjects: 486
Study 8293756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol therapy
Number of subjects: 486
Study 8293756 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of prior antiarrhythmic therapy
Number of subjects: 486
Study 8293756 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up of patients discharged on a drug predicted to be effective
Number of subjects: 486
Study 3720045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, Metoprolol, or Isosorbide Dinitrate (therapy period)
Number of subjects: 187
Study 3720045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (absence of therapy)
Number of subjects: 187
Study 3720045 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (in 76 patients)
Number of subjects: 187
Study 30345475 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum-based fluid thickener
Number of subjects: 22
Study 30345475 — intervention group
Group type: COMPARATOR
Intervention: Control (no xanthan gum-based fluid thickener)
Number of subjects: 22
Study 27660596 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal transcutaneous electrical nerve stimulation (TENS) applied while walking
Number of subjects: 0
Study 27660596 — intervention group
Group type: COMPARATOR
Intervention: Placebo paraspinal TENS applied while walking
Number of subjects: 0
Study 24163212 — intervention group
Group type: EXPERIMENTAL
Intervention: O-Cam
Number of subjects: 152
Study 24163212 — intervention group
Group type: COMPARATOR
Intervention: Cyberball
Number of subjects: 152
Study 24163212 — intervention group
Group type: COMPARATOR
Intervention: Recall
Number of subjects: 152
Study 22404431 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg body mass
Number of subjects: 9
Study 22404431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 20515418 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine (TZV)
Number of subjects: 207
Study 20515418 — intervention group
Group type: COMPARATOR
Intervention: NRTIs/PI (standard ART)
Number of subjects: 207
Study 20515418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TZV and NRTIs/PI
Number of subjects: 207
Study 18541083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterilized paper towel cleaning method
Number of subjects: 75
Study 18541083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline cleaning method
Number of subjects: 75
Study 18541083 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap cleaning method
Number of subjects: 75
Study 15976759 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Thrombelastograph (TEG)
Number of subjects: 43
Study 15976759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletworks (PWA)
Number of subjects: 43
Study 15976759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 43
Study 15976759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen effect size thresholds
Number of subjects: 43
Study 12760311 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 29
Study 10486670 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/day) possibly associated with enalapril (5-20 mg/day) and/or hydrochlorothiazide (12.5-25 mg/day)
Number of subjects: 2438
Study 10486670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2438
Study 8961036 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-450 mg daily)
Number of subjects: 183
Study 8961036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-40 mg daily)
Number of subjects: 183
Study 8961036 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 183
Study 1924565 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (1:250,000, 1:500,000, or 1:1,000,000)
Number of subjects: 26
Study 1924565 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 26
Study 1924565 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 26
Study 31963378 — intervention group
Group type: EXPERIMENTAL
Intervention: Established T2DM
Number of subjects: 540
Study 31963378 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed T2DM
Number of subjects: 540
Study 31963378 — intervention group
Group type: EXPERIMENTAL
Intervention: Established T2DM with severe endothelial dysfunction (FMD < 2%)
Number of subjects: 540
Study 31963378 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed T2DM with non-severe endothelial dysfunction (FMD ≥ 2%)
Number of subjects: 540
Study 31075423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (workshops for GPs and PTs)
Number of subjects: 393
Study 31075423 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 393
Study 27540824 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength exercise program
Number of subjects: 35
Study 27540824 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program
Number of subjects: 35
Study 27540824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as no exercise)
Number of subjects: 35
Study 25670364 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 injections (subcutaneous)
Number of subjects: 97
Study 25670364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 24313693 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based acceptance and commitment therapy (ACT)
Number of subjects: 76
Study 24313693 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 76
Study 23033926 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐Epoetin 40000 IU
Number of subjects: 80
Study 23033926 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐Epoetin 20000 IU
Number of subjects: 80
Study 23033926 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 80
Study 18752998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac (123)I-MIBG scintigraphy in idiopathic RBD patients with or without OSA
Number of subjects: 63
Study 18752998 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed H/M cut-off value of 1.97
Number of subjects: 63
Study 17156226 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII
Number of subjects: 0
Study 17156226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14981374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal fibronectin
Number of subjects: 97
Study 14981374 — intervention group
Group type: COMPARATOR
Intervention: Standard management without fetal fibronectin
Number of subjects: 97
Study 11679600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (10 mL sprayed onto the wound before tourniquet deflation and wound closure)
Number of subjects: 53
Study 11679600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 53
Study 11679600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 53
Study 11679600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 9520606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate violence intervention (domestic violence program)
Number of subjects: 0
Study 9520606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing abuse
Number of subjects: 0
Study 9520606 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse
Number of subjects: 0
Study 9520606 — intervention group
Group type: EXPERIMENTAL
Intervention: Injuries from abuse
Number of subjects: 0
Study 8083097 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated multiple daily fraction radiation (44.40 Gy in 12 fractions, 3.7 Gy BID)
Number of subjects: 290
Study 8083097 — intervention group
Group type: COMPARATOR
Intervention: 2-week rest interval
Number of subjects: 290
Study 8083097 — intervention group
Group type: COMPARATOR
Intervention: 4-week rest interval
Number of subjects: 290
Study 2577482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg nocte for 4 weeks
Number of subjects: 0
Study 2577482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte for 4 weeks
Number of subjects: 0
Study 2577482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg nocte for 4 weeks
Number of subjects: 0
Study 2577482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 334210 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 microgram/kg
Number of subjects: 172
Study 334210 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 microgram/kg
Number of subjects: 172
Study 334210 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1 mg/kg
Number of subjects: 172
Study 334210 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 0.6 mg/kg
Number of subjects: 172
Study 31744527 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29044008 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon
Number of subjects: 120
Study 29044008 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 120
Study 25765965 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow growth BCG batches
Number of subjects: 1633
Study 22630616 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg for the first 5 days and 100 mg on days 6 and 7)
Number of subjects: 19
Study 22630616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22093474 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP-T combined vaccine (PENTAXIM(TM)) vaccinated at 2, 3, 4 months of age
Number of subjects: 0
Study 22093474 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP-T combined vaccine (PENTAXIM(TM)) vaccinated at 3, 4, 5 months of age
Number of subjects: 0
Study 22093474 — intervention group
Group type: COMPARATOR
Intervention: Control group: DTaP, Hib tetanus conjugate (Act-HIB(TM)), and IPV (IMOVAX PolioTM(TM)) vaccines vaccinated at 3, 4, 5 months of age
Number of subjects: 0
Study 22093474 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP-T combined vaccine
Number of subjects: 0
Study 19451321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tenofovir gel
Number of subjects: 36
Study 19451321 — intervention group
Group type: COMPARATOR
Intervention: K‐Y Jelly
Number of subjects: 36
Study 16752255 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT and TLFB screening
Number of subjects: 315
Study 16752255 — intervention group
Group type: COMPARATOR
Intervention: Regular antenatal care
Number of subjects: 315
Study 15209605 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily for 6 months
Number of subjects: 152
Study 15209605 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily for 12 months
Number of subjects: 152
Study 15209605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 11270027 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mL 0.9% saline (Group A)
Number of subjects: 30
Study 11270027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL 1% lidocaine (Group B)
Number of subjects: 30
Study 11270027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL dexamethasone (4 mg) (Group C)
Number of subjects: 30
Study 9266515 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin (10-40 mg/day)
Number of subjects: 45
Study 9266515 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (20-80 mg/day)
Number of subjects: 45
Study 8338047 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol concentrations
Number of subjects: 0
Study 8338047 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria parasite density
Number of subjects: 0
Study 3334238 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary suture
Number of subjects: 57
Study 3334238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fibre augmentation
Number of subjects: 57
Study 3334238 — intervention group
Group type: COMPARATOR
Intervention: Primary suture vs Carbon fibre augmentation
Number of subjects: 57
Study 31926158 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic air-extraction catheter (intervention group)
Number of subjects: 96